Antibiotic resistance in enterobacteria

Bacterial Resistance to Antimicrobials, Second Edition

Volumn , Issue , 2007, Pages 343-362

  Georgopapadakou, Nafsika H ^a  

^a METHYLGENE INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886875671     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (167)

1. Holt JG, Krieg NR, Sneath PHA, Staley JT, Williams ST (eds) Bergey’s Manual of Determinative Bacteriology, 9th ed. Baltimore: Williams & Wilkins, 1993.
2. Dykhuizen DE. Yersinia pestis: an instant species? Trends Microbiol 2000; 8:296-8.
3. Achtman M, Zurth K, Morelli G, Torrea G, Guiyoule A, Carniel E. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci USA 1999; 96:14043-8.
4. Skurnik M, Peippo A, Ervela E. Characterization of the O-antigen gene clusters of Yersinia pseudotuberculosis and the cryptic O-antigen gene cluster of Yersinia pestis shows that the plague bacillus is most closely related to and has evolved from Y. pseudotuberculosis serotype O:1b. Mol Microbiol 2000; 37:316-30.
5. Derbise A, Chenal-Francisque V, Pouillot F, Fayolle C, Prevost MC, Medigue C, Hinnebusch BJ, Carniel E. A horizontally acquired filamentous phage contributes to the pathogenicity of the plague bacillus. Mol Microbiol 2007; 63:1145-57.
6. Ligon BL. Plague: a review of its history and potential as a biological weapon. Semin Pediatr Infect Dis 2006; 17:161-70.
7. Armstrong GL, Hollingsworth J, Morris JG Jr. Emerging foodborne pathogens:Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Epidemiol Rev 1996; 18, 29-51.
8. Hacker J, Blum-Oehler G, Muhldorfer I, Tschape H. Pathogenicity islands of virulent bacteria: structure, function and impact on microbial evolution. Mol Microbiol 1997; 23:1089-97.
9. Wood MW, Jones MA, Watson PR, Hedges S, Wallis TS, Galyov EE. Identification of a pathogenicity island required for Salmonella enteropathogenicity. Mol Microbiol 1998; 29:883-91.
10. Hensel M, Nikolaus T, Egelseer C. Molecular and functional analysis indicates a mosaic structure of Salmonella pathogenicity island 2. Mol Microbiol 1999; 31:489-98.
11. Vokes SA, Reeves SA, Torres AG, Payne SM. The aerobactin iron transport system genes in Shigella flexneri are present within a pathogenicity island. Mol Microbiol 1999; 33:63-73.
12. Hacker J, Hochhut B, Middendorf B, Schneider G, Buchrieser C, Gottschalk G, Dobrindt U. Pathogenomics of mobile genetic elements of toxigenic bacteria. Int J Med Microbiol 2004; 293:453-61.
13. Deng W, Puente JL, Gruenheid S, Li Y, Vallance BA, Vazquez A, Barba J, Ibarra JA, O’Donnell P, Metalnikov P, Ashman K, Lee S, Goode D, Pawson T, Finlay BB. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci USA 2004; 101:3597-602.
14. Tenover FC, McGowan JE Jr. Reasons for the emergence of antibiotic resistance. Am J Med Sci 1996; 311:9-16.
15. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist Updates 2000; 3:303-311.
16. Stohr K, Wegener HC. Animal use of antimicrobials: impact on resistance. Drug Resist Updates 2000; 3:207-209.
17. Angulo FJ, Johnson KR, Tauxe RV, Cohen ML. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella : implications for the use of fluoroquinolones in food animals. Microb Drug Resist 2000; 6:77-83.
18. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant Salmonella enterica serotype Typhimurium DT104 infections in the United States. N Engl J Med 1998; 338:1333-8.
19. Akkina JE, Hogue AT, Angulo FJ, Johnson R, Petersen KE, Saini PK, Fedorka-Cray PJ, Schlosser WD. Epidemiologic aspects, control, and importance of multiple-drug resistant Salmonella typhimurium DT104 in the United States. J Am Vet Med Assoc 1999; 214:790-8.
20. Briggs CE, Fratamico PM. Molecular characterization of an antibiotic resistance gene cluster of Salmonella typhimurium DT104. Antimicrob Agents Chemother 1999; 43:846-9.
21. Angulo FJ, Griffin PM. Changes in antimicrobial resistance in Salmonella enterica serovar Typhimurium [letter]. Emerg Infect Dis 2000; 6:436-8.
22. Hughes JM, Tenover FC. Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Clin Infect Dis 1997; 24 (Suppl 1):S131-5.
23. Podzorski RP, Persing DH. Molecular detection and identification of microorganisms. In: Murray PR, Baron JE, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology, 6th ed. Washington DC: ASM Press, 1995:130-157.
24. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
25. Tenover FC, Arbeit RD, Goering RV. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular TypingWorking Group of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1997; 18:6,426-39.
26. Courvalin P. Impact of molecular biology on antibiotic susceptibility: testing and therapy. Am J Med 1995; 99 (6A):21S-25S.
27. Tenover FC. Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. Clin Infect Dis 2007; 44:418-23.
28. Giles WP, Benson AK, Olson ME, Hutkins RW, Whichard JM, Winokur PL, Fey PD. DNA sequence analysis of regions surrounding blaCMY-2 from multiple Salmonella plasmid backbones. Antimicrob Agents Chemother 2004; 48:2845-52.
29. Hiraoka M, Okamoto R, Inoue M, Mitsuhashi S. Effects of β-lactamases and omp mutation on susceptibility to β-lactam antibiotics in Escherichia coli. Antimicrob Agents Chemother 1989; 33:382-386.
30. Bauernfeind A, Georgopapadakou NH. Clinical significance of antibacterial transport. In Georgopapadakou NH (ed). Drug transport in antimicrobial and anticancer chemotherapy. New York: Marcel Dekker, 1995:1-19.
31. Courvalin P. Transfer of antibiotic resistance genes between Gram-positive and Gramnegative bacteria. Antimicrob Agents Chemother 1994; 38:1447-51.
32. Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P. Modes and modulations of antibiotic resistance gene expression. Clin Microbiol Rev 2007; 20:79-114.
33. Hall RM, Collis CM. Antibiotic resistance in Gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist Updates 1998; 1:109-119.
34. Hall RM. Mobile gene cassettes and integrons: moving antibiotic resistance genes in Gram-negative bacteria. Ciba Found Symp 1997; 207:192-202; discussion 202-5.
35. Liebert CA, Hall RM, Summers AO. Transposon Tn21, flagship of the floating genome. Microbiol Mol Biol Rev 1999; 63:507-22.
36. Skold O. Sulfonamide resistance: mechanisms and trends. Drug Resist Updates 2000; 3:155-160.
37. Poirel L, Cattoir V, Soares A, Soussy CJ, Nordmann P. Novel Ambler class A β-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. Antimicrob Agents Chemother 2007; 51:631-7.
38. Pai H, Seo MR, Choi TY. Association of QnrB determinants and production of extended-spectrum β-lactamases or plasmid-mediated AmpC β-lactamases in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 2007; 51:366-8
39. Neuhaus FC, Georgopapadakou NH. Strategies in β-lactam design. In Sutcliffe JA, Georgopapadakou NH (eds). Emerging targets in antibacterial and antifungal chemotherapy. New York: Chapman & Hall, 1992:204-273.
40. Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob Agents Chemother 1993; 37:2045-53.
41. Ghuysen JM. Serine β-lactamases and penicillin-binding proteins. Annu Rev Microbiol 1991;45:37-67.
42. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289:321-31.
43. Ledent P, Raquet X, Joris B, Van Beeumen J, Frere JM. A comparative study of class-D β-lactamases. Biochem J 1993; 292:555-62.
44. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39:1211-33.
45. Rice LB, Bonomo RA. β-Lactamases: which ones are clinically important? Drug Resist Updates 2000; 3:178-89.
46. Jacoby GA, Munoz-Price LS. The new β-lactamases. New Engl J Med 2005; 352:380-91.
47. Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. J Antimicrob Chemother 2006 Mar;57(3):373-83.
48. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12:223-30.
49. Wong JD, Barash JR, Sandfort RF, Janda JM. Susceptibilities of Yersinia pestis strains to 12 antimicrobial agents. Antimicrob Agents Chemother 2000; 44:1995-6.
50. Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E, Courvalin P. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997; 337:10, 677-80.
51. Rice LB, Carias LL, Hujer AM, Bonafede M, et al. High-level expression of chromosomally encoded SHV-1 β-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin/tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44:362-367.
52. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, Steward C, Hill B, Medeiros AA, Tenover FC. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41:647-53.
53. Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Domenech-Sanchez A, Swenson JM, Biddle JW, Ferraro MJ, Jacoby GA, Tenover FC. Characterization of the extendedspectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 2000; 44:9, 2382-8.
54. Coque TM, Oliver A, Perez-Diaz JC, Baquero F, Canton R. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum β-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2002; 46:500-10.
55. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48:1-14.
56. Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006; 9:466-75.
57. Jacoby GA. Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino-β-lactams. Infect Dis Clin North Am 1997; 11: 4, 875-87.
58. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18(2):306-25.
59. Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-β-lactamase-producing Gram-negative bacilli in the clinical laboratory. J Clin Microbiol 2006; 44:3139-44.
60. Georgopapadakou NH. 2004. β-Lactamase inhibitors: evolving compounds for evolving resistance targets. Expert Opin Investig Drugs 2004; 13:1307-1318.
61. MGP Page. β-Lactamase inhibitors. Drug Resist Updates 2000; 3:109-125.
62. Stapleton PD, Shannon KP, French GL. Construction and characterization of mutants of the TEM β-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors. Antimicrob Agents Chemother 1999; 43:1881-1887.
63. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. J Am Med Assoc 1998; 280:1233-37.
64. Lucet JC, Decre D, Fichelle A, et al. Control of a prolonged outbreak of extendedspectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29:1411-1418.
65. Monnet DL, Biddle JW, Edwards JR, Culver DH, Tolson JS, Martone WJ, Tenover FC, Gaynes RP. Evidence of interhospital transmission of extended-spectrum β-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. The National Nosocomial Infections Surveillance System. Infect Control Hosp Epidemiol 1997; 18: 7, 492-8
66. Tenover FC, Mohammed MJ, Gorton TS, Dembek ZE. Detection and reporting of organisms producing extended-spectrum β-lactamases: survey of laboratories in Connecticut. J Clin Microbiol 1999; 37:4065-70.
67. Laboratory capacity to detect antimicrobial resistance. MMWR Morb Mortal Wkly Rep 2000; 48:1167-71.
68. Martinez-Martinez L, Conejo MC, Pascual A, Hernandez-Alles S, Ballesta S, Ramirez De Arellano-Ramos E, Benedi VJ, Perea EJ. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal β-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 2000; 44:2534-6.
69. Joris B, De Meester F, Galleni M, Frere JM, Van Beeumen J. The K1 β-lactamase of Klebsiella pneumoniae. Biochem J 1987; 243:561-7.
70. Martinez-Martinez L, Pascual A, Hernandez-Alles S, Alvarez-Diaz D, Suarez AI, Tran J, Benedi VJ, Jacoby GA. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999; 43:1669-73.
71. Weindorf H, Schmidt H, Martin HH. Contribution of overproduced chromosomal β-lactamase and defective outer membrane porins to resistance to extended-spectrum β-lactam antibiotics in Serratia marcescens. J Antimicrob Chemother 1998; 41:189-95.
72. Wiedemann B, Pfeiffle D, Wiegand I, Janas E. β-Lactamase induction and cell wall recycling in Gram-negative bacteria. Drug Resist Updates 1998; 1:223-226.
73. Jacobs C. Life in the balance: cell walls and antibiotic resistance. Science 1997; 278:1731-1732.
74. Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985; 49:1-32.
75. Georgopapadakou NH. Antibiotic permeation through the bacterial outer membrane. J Chemother 1990; 2:275-9.
76. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67:593-656.
77. Alcantar-Curiel MD, Garcia-Latorre E, Santos JI. Klebsiella pneumoniae 35 and 36 kDa porins are common antigens in different serotypes and induce opsonizing antibodies. Arch Med Res 2000; 31:28-36.
78. Hernandez-Alles S, Alberti S, Alvarez D, Domenech-Sanchez A, Martinez-Martinez L, Gil J, Tomas JM, Benedi VJ. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 1999; 145: 673-9.
79. Hutsul JA, Worobec E. Molecular characterization of the Serratia marcescens OmpF porin, and analysis of S. marcescens OmpF and OmpC osmoregulation. Microbiology 1997; 143: 2797-806.
80. Chevalier J, Pages JM, Mallea M. In vivo modification of porin activity conferring antibiotic resistance to Enterobacter aerogenes. Biochem Biophys Res Commun 1999; 266:248-51.
81. Mallea M, Chevalier J, Bornet C, Eyraud A, Davin-Regli A, Bollet C, Pages JM. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 1998; 144:3003-9.
82. Domenech-Sanchez A, Hernandez-Alles S, Martinez-Martinez L, Benedi VJ, Alberti S. Identification and characterization of a new porin gene of Klebsiella pneumoniae : its role in β-lactam antibiotic resistance. J Bacteriol 1999; 181:2726-32.
83. Bjorkman J, Andersson DI. The cost of antibiotic resistance from a bacterial perspective. Drug Resist Updates 2000; 3:237-245.
84. Chapman JS, Georgopapadakou NH. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother 1988; 32:438-42.
85. McCaffrey C, Bertasso A, Pace J, Georgopapadakou NH. Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Antimicrob Agents Chemother 1992; 36:1601-5.
86. Hooper DC. Mode of action of fluoroquinolones. Drugs 1999; 58 (Suppl 2):6-10.
87. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001.
88. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351:797-9.
89. Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004; 48:1295-9.
90. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005; 56:463-9.
91. Poirel L, Nordmann P, De Champs C., Eloy C. Nosocomial spread of QnrA-mediated quinolone resistance in Enterobacter sakazakii. Int J Antimicrob Agents 2007; 29:223-4.
92. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6(10):629-40.
93. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006; 50(11):3953-5.
94. Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998; 42:10, 2661-7.
95. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updates 1999; 2:38-55.
96. Yoshida H, Bogaki M, Nakamura M et al. Quinolone-resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34:1271-2.
97. Breines DM, Ouabdesselam S, Ng EY, Tankovic J, Shah S, Soussy CJ, Hooper DC. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother 1997; 41:175-9.
98. Georgopapadakou NH. Quinolone uptake and efflux. In Georgopapadakou NH (ed). Drug transport in antimicrobial and anticancer chemotherapy. New York: Marcel Dekker, 1995:245-267.
99. Cohen SP, Hooper DC, Wolfson JS et al. An endogenous active efflux of norfloxacin in Escherichia coli. Antimicrob Agents Chemother 1988; 32:1187-91.
100. Chapman JS, Bertasso A, Georgopapadakou NH. Fleroxacin resistance in Escherichia coli. Antimicrob Agents Chemother 1989; 33:239-41.
101. Ishii H, Sato K, Hoshino K et al. Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris. J Antimicrob Chemother 1991; 28:827-36.
102. O’Hara CM, Steward CD, Wright JL, Tenover FC, Miller JM. Isolation of Enterobacter intermedium from the gallbladder of a patient with cholecystitis. J Clin Microbiol 1998; 36:3055-6.
103. Dworkin RJ. Aminoglycosides for the treatment of Gram-negative infections: therapeutic use, resistance and future outlook. Drug Resist Updates 1999; 2:173-9.
104. Wright GD, Berghuis AM, Mobashery S. Aminoglycoside antibiotics. Structures, functions, and resistance. Adv Exp Med Biol 1998; 456:27-69.
105. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000; 44:3249-56.
106. Davies JE. Aminoglycosides: ancient and modern. J Antibiot 2006; 59:529-32.
107. Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996; 274:1367-71.
108. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987; 327:389-94.
109. Bryan LE. Mechanisms of action of aminoglycoside antibiotics. In Root RK, Sande MA (eds). New dimensions in antimicrobial therapy. New York: Churchill-Livingstone, 1984:17-36.
110. Bryan LE, Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother 1983; 23:835-45.
111. Davies J, Wright GD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997; 5:234-40.
112. Gerding DN, Larson TA, Hughes RA et al. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35:1284-90.
113. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 1999; 18:414-21.
114. Busch-Sorensen C, Sonmezoglu M, Frimodt-Moller N, Hojbjerg T, Miller GH, Espersen F. Aminoglycoside resistance mechanisms in Enterobacteriaceae and Pseudomonas spp. from two Danish hospitals: correlation with type of aminoglycoside used. APMIS 1996; 104:763-8.
115. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57:138-63.
116. Thompson PR, Schwartzenhauer J, Hughes DW, Berghuis AM, Wright GD. The COOH terminus of aminoglycoside phosphotransferase (3')-IIIa is critical for antibiotic recognition and resistance. J Biol Chem 1999; 274:43, 30697-706.
117. Sandvang D, Aarestrup FM. Characterization of aminoglycoside resistance genes and class 1 integrons in porcine and bovine gentamicin-resistant Escherichia coli. Microb Drug Resist 2000; 6:19-27.
118. Lambert T, Gerbaud G, Courvalin P. Characterization of transposon Tn1528, which confers amikacin resistance by synthesis of aminoglycoside 3'-O-phosphotransferase type VI. Antimicrob Agents Chemother 1994; 38:702-6.
119. Wu HY, Miller GH, Blanco MG, Hare RS, Shaw KJ. Cloning and characterization of an aminoglycoside 6'-N -acetyltransferase gene from Citrobacter freundii which confers an altered resistance profile. Antimicrob Agents Chemother 1997; 41:2439-47.
120. Rather PN. Origins of the aminoglycoside-modifying enzymes. Drug Resist Updates 1998; 1:285-291.
121. Perlin MH, Lerner SA. High-level amikacin resistance in E. coli due to phosphorylation and impaired aminoglycoside uptake. Antimicrob Agents Chemother 1986; 29:216-24.
122. Acosta MB, Ferreira RC, Padilla G, Ferreira LC, Costa SO. Altered expression of oligopeptide-binding protein (OppA) and aminoglycoside resistance in laboratory and clinical Escherichia coli strains. J Med Microbiol 2000; 49:409-13.
123. Kashiwagi K, Tsuhako MH, Sakata K, Saisho T, Igarashi A, da Costa SO, Igarashi K. Relationship between spontaneous aminoglycoside resistance in Escherichia coli and a decrease in oligopeptide binding protein. J Bacteriol 1998; 180:5484-8.
124. Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992; 29:245-77.
125. Shlaes DM. An update on tetracyclines. Curr Opin Investig Drugs 2006; 7:167-71.
126. Chopra I. Tetracycline uptake and efflux in bacteria. In Georgopapadakou NH (ed). Drug transport in antimicrobial and anticancer chemotherapy. New York: Marcel Dekker, 1995:221-243.
127. Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 1993; 37:1393-9.
128. Speer BS, Shoemaker NB, Salyers AA: Bacterial resistance to tetracycline: mechanisms, transfer, and clinical implications. Clin Microbiol Rev 1992; 5:387-99.
129. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992; 36:695-703.
130. Thanassi DG, Suh GS, Nikaido H. Role of outer membrane barrier in efflux-mediated tetracycline resistance of Escherichia coli. J Bacteriol 1995; 177:998-1007.
131. Levy SB, McMurry LM, Barbosa TM, Burdett V, Courvalin P, Hillen W, Roberts MC, Rood JI, Taylor DE. Nomenclature for new tetracycline resistance determinants. Antimicrob Agents Chemother 1999; 43:6, 1523-4.
132. McMurry LM, Petrucci RE, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistant determinants in Escherichia coli. Proc Natl Acad Sci USA 1980; 77:3974-7.
133. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev 1996; 19:1-24.
134. Roberts MC. Genetic mobility and distribution of tetracycline resistance determinants. Ciba Found Symp 1997; 207:206-18; discussion 219-22.
135. Makino S, Asakura H, Obayashi T, Shirahata T, Ikeda T, Takeshi K. Molecular epidemiological study on tetracycline resistance R plasmids in enterohaemorrhagic Escherichia coli O157:H7. Epidemiol Infect 1999; 123:25-30.
136. Magalhaes VD, Schuman W, Castilho BA. A new tetracycline resistance determinant cloned from Proteus mirabilis. Biochim Biophys Acta 1998; 1443:262-6.
137. Taylor DE, Chau A. Tetracycline resistance mediated by ribosomal protection. Anti microb Agents Chemother 1996; 40:1-5.
138. Oliva B, Chopra I. tet Determinants provide poor protection against some tetracyclines:further evidence for division of tetracyclines into two classes. Antimicrob Agents Chemother 1992; 36:876-8.
139. Testa RT, Petersen PJ, Jacobus NV et al. In vitro and in vivo antibacterial activities of the glycylglycines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37:2270-7.
140. Tally FT, Ellestad GA, Testa RT. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother 1995; 35:449-52.
141. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738-44.
142. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006; 28(8):1079-106.
143. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43(4):518-24.
144. Nelson ML, Levy SB. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 1999; 43:1719-24.
145. Huovinen P, Sundstrom L, Swedberg G, Skold O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 1995; 39:279-89.
146. Swedberg G, Skold O. Characterization of different plasmid-borne dihydropteroate synthases mediating bacterial resistance to sulfonamides. J Bacteriol 1980; 142:1-7.
147. Radstrom P, Swedberg G. RSF1010 and a conjugative plasmid contain sulII, one of the two known genes for plasmid-borne sulfonamide resistant dihydropteroate synthase. Antimicrob Agents Chemother 1988; 32:1684-92.
148. Sundstrom L, Radstrom P, Swedberg G, Skold O. Site-specific recombination promotes linkage between trimethoprim-and sulfonamide resistance genes. Sequence characterization of dhfrV and sulI and a recombination active locus of Tn21. Mol Gen Genet 1988; 213:191-201.
149. Amyes SGB, Towner KJ. Trimethoprim resistance: epidemiology and molecular aspects. J Med Microbiol 1990; 31:1-9.
150. Grey D, Hamilton-Miller JMT, Brumfitt W. Incidence and mechanisms of resistance to trimethoprim in clinically isolated Gram-negative bacteria. Chemotherapy 1979; 25:147-56.
151. Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997; 24(Suppl 10): S63-6.
152. Shaw WV. Chloramphenicol acetyltransferase: enzymology and molecular biology. Crit Rev Biochem 1983; 14:1-46.
153. Parent R, Roy PH. The chloramphenicol acetyltransferase gene of Tn2424: a new breed of cat. J Bacteriol 1992; 174:2891-7.
154. Arcangioli MA, Leroy-Setrin S, Martel JL, Chaslus-Dancla E. Evolution of chloramphenicol resistance, with emergence of cross-resistance to florfenicol, in bovine Salmonella typhimurium strains implicates definitive phage type (DT) 104. J Med Microbiol 2000; 49:103-10.
155. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 2004; 28(5):519-42.
156. Centers for Disease Control and Prevention/National Nosocomial Infections Surveillance System. Semiannual report. December 1999 (corrected March 2000) Atlanta, Ga:CDC/NNIS. 2000 [database online: http://www.cdc.gov/ncidod/hip/NNIS/dec99sar. pdf].
157. Jacoby GA. Antimicrobial-resistant pathogens in the 1990s. Annu Rev Med 1996; 47:169-79.
158. Struelens MJ, Byl B, Vincent J-L. Antibiotic policy: a tool for controlling resistance of hospital pathogens. Clin Microbiol Infect 1999; 5:S19-S24.
159. Flynn DM, Weinstein RA, Nathan C et al. Patients’ endogenous flora as the source of “nosocomial” Enterobacter in cardiac surgery. J Infect Dis 1987; 156:363-8.
160. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. J Am Med Assoc 1999; 281:736-8.
161. Wiener J, Quinn JP, Bradford PA et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. J Am Med Assoc 1999; 281:517-23.
162. Guyot A, Barrett SP, Threlfall EJ, Hampton MD, Cheasty T. Molecular epidemiology of multi-resistant Escherichia coli. J Hosp Infect 1999; 43:39-48.
163. Nikaido H. The role of outer membrane and efflux pumps in the resistance of Gramnegative bacteria. Can we improve access? Drug Resist Updates 1998; 1:93-98.
164. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56(1):20-51.
165. Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 2000; 182:3142-50.
166. Hancock REW. Alterations in outer membrane permeability. Annu Rev Microbiol 1984; 38:237.
167. Viljanen P, Kayhty H, Vaara M, Vaara T. Susceptibility of Gram-negative bacteria to the synergistic bactericidal action of serum and polymyxin B nonapeptide. Can J Microbiol 1986; 32:66-9.